Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of orally available selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its lead product candidate, AT-527, is an orally administered, antiviral agent for the treatment of patients infected with SARS-CoV-2. It provides AT-787 for the treatment of hepatitis C. It offers AT-752 for the treatment of dengue, which is an oral, purine nucleotide prodrug for the treatment of dengue virus, a mosquito-borne viral infection. The Company is evaluating two lead compounds, AT-889 and AT-934, nucleoside pyrimidine prodrugs and other compounds for the treatment of respiratory syncytial virus (RSV).